Good CSV documentation is the smallest set of records that proves a computerized system is fit for its intended use and stays that way. It is scaled to risk, traceable from requirement to test result, and built from evidence the system already generates. It is not a thicker binder. (This article covers computerized system validation in regulated life sciences. If you landed here looking for comma-separated files, see the short note near the end.)
Most validation teams already know this in principle. The trouble is practice: templates inherited from 2008, screenshots pasted into Word, and a traceability matrix rebuilt by hand the week before an inspection. Below is what to keep, what to drop, and how to make the records you keep defensible.
TL;DR
- Validation documentation is evidence of a state of control, not a stack of paper. Write less, but make every record traceable and attributable.
- Scale depth to intended use and risk to patient safety or product quality. FDA's February 2026 CSA guidance and GAMP 5 Second Edition both point this way.
- Prefer system-generated evidence (logs, audit trails, automated test results) over manual screenshots, provided the records stay accurate, complete and secure.
- Treat audit trail review and ALCOA+ as part of the documentation set, not an afterthought.
- Automate drafting and traceability where you can, but keep human signatures authoritative.
Table of Contents
- What CSV documentation is actually for
- The core documents, and how lean each can be
- Write to risk, not to habit
- Use system-generated evidence instead of screenshots
- Build ALCOA+ into every record
- Make the traceability matrix a living record
- Audit trails are documentation too
- Our perspective
- A practical workflow for your next system
- Where tooling helps
- Common mistakes to retire
- A note on comma-separated files
- FAQ
- Sources
What CSV documentation is actually for
A validation package answers three questions an inspector will ask in some form. What is this system supposed to do? How do you know it does that? What keeps it that way?
Everything in the package should map to one of those. A user requirement specification (URS) answers the first. Test protocols and their executed results answer the second. Change control, periodic review, access management and audit trail review answer the third.
The GAMP 5 Second Edition commentary from CASRAI describes the shift well: the first edition was often read as a documentation-heavy exercise, and the second edition's emphasis is on critical thinking about evidence. The deliverable is the demonstrated state of control, not the document that describes it. That framing is the best filter for every decision below. If a document does not help prove one of the three questions, it is a candidate for removal.
For a fuller grounding in the framework, see our practical guide to GAMP 5 validation and the piece on GAMP 5's risk-based approach.
The core documents, and how lean each can be
The set below covers most GxP systems. Depth varies by risk and software category; the list does not.
| Document | Purpose | Where to trim |
|---|---|---|
| Validation plan (VP/VMP) | Scope, roles, approach, acceptance criteria | One short plan per system or family of similar systems; reference the site VMP instead of repeating it |
| URS | What the business and compliance need | Write testable, uniquely numbered requirements; drop wish lists |
| Risk assessment | Where failure harms patients, product or data | Assess functions, not just the system, so testing effort follows risk |
| Specifications (FS/DS, config) | How the system meets the URS | For configured commercial systems, reference vendor documentation rather than rewriting it |
| Qualification (IQ/OQ/PQ) | Proof of installation, operation and performance | Combine where the system is simple; scripted detail only for high-risk functions |
| Traceability matrix | Requirement to risk to test to result | Keep it live, not rebuilt at the end |
| Validation summary report | Conclusion, deviations, release decision | Short, factual, signed |
| Operational records | Change control, periodic review, audit trail review | Make them routine, not project-time artifacts |
The table is deliberately unglamorous. None of these documents is controversial. What separates a defensible package from a bloated one is how much each contains and whether the links between them hold.
Write to risk, not to habit
Start from intended use
FDA's February 2026 guidance on Computer Software Assurance describes a risk-based approach to establishing confidence in software used in production or the quality system. It focuses on intended use and on risk to patient safety or product quality, and it identifies where additional rigor is appropriate. Note the scope: the guidance is written for medical device production and quality management system software under 21 CFR Part 820. Pharmaceutical and biotech teams are not bound by it in the same way, but many use the same reasoning because it matches GAMP 5 thinking. If you work in devices, our medical device CSV checklist goes deeper.
In practice, "start from intended use" means writing one sentence per system before anything else: who uses it, for which GxP decision, and what happens if it fails silently. That sentence drives the risk assessment, and the risk assessment drives everything after it.
Scale test depth to risk
A useful rule of thumb that fits both CSA and GAMP 5 logic:
- High risk (function directly affects patient safety, product quality or data integrity): scripted testing with predefined expected results, independent review.
- Medium risk: limited scripted testing or unscripted testing with a documented objective and recorded result.
- Low risk: rely on vendor evidence, standard configuration checks and routine use, with a brief rationale recorded.
The rationale is the documentation. A one-paragraph note explaining why a low-risk reporting function got no scripted test is stronger than ten pages of scripts nobody could justify.
Stop treating volume as compliance
The CASRAI commentary notes that organizations often fail through bloated documentation that adds no compliance value. A risk-based approach lets you concentrate effort on what affects patient safety and product quality. Sentences like "we always test everything" read well internally and badly during an inspection, because they show no thinking.
Use system-generated evidence instead of screenshots
One of the most practical shifts is how test evidence is captured. The FDA CSA guidance, in the text hosted by GMP Compliance, says the record should capture enough objective evidence to show the function was assessed and performs as intended. It also encourages digital retention of results, automated traceability and automated testing, and the use of existing system logs and audit trails as objective evidence rather than duplicative paper records or screenshots. The condition is that these digital records keep their accuracy, reliability, integrity, availability and authenticity.
That condition matters. A log is only good evidence if you can show it cannot be quietly altered and that it is complete. So the practice is:
- Capture results from the system or test tool directly, with user, date and time stamped by the system.
- Record pass/fail and the tester's identity, not a gallery of images.
- Keep screenshots only where a visual state is the evidence, such as a label layout or a displayed warning.
- Retain raw outputs in a controlled, searchable repository so they are available for the whole retention period.
The same logic is behind a well-run automated validation documents approach for audit-ready records.
Build ALCOA+ into every record
Records fail inspections less often because the science is wrong than because the record is not trustworthy. ICH E6(R3) expects robust processes for managing records so that integrity and traceability are maintained. The ALCOA+ attributes are: attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring and available. The EMA guideline on computerised systems and electronic data in clinical trials frames data integrity in the same terms, and the MHRA GxP data integrity guidance promotes a risk-based approach across the data lifecycle.
For validation documents specifically, translate each attribute into a check someone can actually run:
- Attributable: every author, tester, reviewer and approver is identifiable by individual account, not a shared login.
- Contemporaneous: test results are recorded at execution, not reconstructed afterward.
- Original: the first capture is preserved; transcribed copies are verified copies.
- Complete: deviations and failed attempts stay in the record with their resolution.
- Enduring and available: the package can be retrieved and read years later, in a readable format.
Our pieces on ALCOA+ examples, write-time ALCOA+ audit fields and a data integrity compliance playbook give concrete cases.
Make the traceability matrix a living record
The matrix is the document inspectors use to test your package, because one question exposes weakness fast: "Show me how this requirement was tested." If you can click from requirement to risk to test to result in seconds, the package is credible. If someone has to open four files and a spreadsheet, it is not.
Good practice:
- Give every requirement a unique ID that never gets reused, even when the requirement is retired.
- Link each requirement to its risk rating and to the specific test or evidence that covers it.
- Update the matrix when requirements change, not at the end of the project.
- Record the version of each linked document, so the matrix shows state at the time of release.
A matrix maintained by hand drifts. This is the single place where tooling pays for itself fastest.
Audit trails are documentation too
Annex 11 of the EU GMP rules on computerised systems expects audit trails for GMP-relevant changes and deletions, and for the system to record who did what and when. Under the EU and EMA expectations, the audit trail needs to be secure, computer-generated and timestamped, enable reconstruction of the event history, and be available in human-readable form for review.
The documentation point is review. The MHRA guidance stresses that review has to be robust and documented, either by reviewing the audit trail lists directly or by using validated exception reporting. A frequent weakness, as inspectors and experts describe it, is treating the audit trail as a log nobody opens. So your documentation set should include:
- A statement of which events are GMP-relevant and therefore audit-trailed.
- A review procedure with frequency set by risk.
- A record each time review happens, including what was looked for and what was found.
If you also ask suppliers to produce records, knowing the difference between GLP and GMP record expectations helps you phrase the request; this overview of GLP versus GMP and how to request Part 58 or 210/211 records is a useful reference for lab managers. For the design side, see our seven elements of GxP audit trail design.
Our perspective
We build validation software, so we see where the hours go. They rarely go into thinking. They go into formatting, copying requirement text into protocols, chasing signatures, pasting screenshots and rebuilding traceability. That is the quiet tax on every validation cycle, and it also creates the fire drill before an audit.
Our view is that the documentation burden should shrink while the evidence gets stronger, and that these two goals do not conflict. Agents can draft URS, protocols and reports from your templates and your source material, keep the traceability matrix live, and check every record against ALCOA+ at the moment it is written and again when it is reviewed. People should then spend their time on what only people can do: judging risk, deciding what matters to the patient, and signing. Human signatures stay authoritative. A draft is a draft until a qualified person owns it.
We also think the deployment model is part of the compliance story. A validation platform that handles your most sensitive quality records should run privately inside your infrastructure, with no data leaving it and encryption keys under your control. Otherwise you have moved a documentation problem into a data-governance problem.
Do not trust any tool, ours included, on its claims alone. Ask to see the audit trail it produces, the way it records review, and how it behaves when a reviewer disagrees with a draft.
— Matt
A practical workflow for your next system
Here is a sequence that keeps documentation proportionate.
- Define intended use in a short paragraph and decide the GxP impact.
- Write testable requirements. If you cannot say how a requirement would be verified, rewrite it.
- Assess risk by function. Record the rating and the reason.
- Leverage the supplier. Review vendor documentation and testing, assess the supplier, and record what you will rely on.
- Test by risk. Scripted where risk is high, lighter where it is not, with rationale for each choice.
- Capture evidence digitally from the system, with identity and timestamp.
- Close deviations with documented impact assessment.
- Report briefly and release with signatures.
- Sustain it: change control, periodic review, audit trail review, access reviews.
Worked example: a quality team validates a configured electronic training management system. Intended use is tracking training completion for GxP roles. Risk is rated high for assignment logic and completion records, low for dashboard cosmetics. The team writes eleven requirements, scripts tests for the high-risk functions, and runs an exploratory session on the dashboard with a one-line record. Results are exported from the test tool with user and time. The summary report fits on three pages. That package is smaller than a legacy one and easier to defend, because every choice has a stated reason.
Where tooling helps
Tools help most with three tasks: authoring from templates, keeping traceability current and checking record quality. Validate·AI and Operate·AI cover the validation lifecycle from URS through OQ/PQ, with a live traceability matrix, deviation and CAPA handling, and ALCOA+ checks at write time and review time. Our platform deploys privately in your infrastructure, integrates with existing quality management systems and is LLM-agnostic. We typically start with a paid pilot on one or two systems so your team can judge the output against your own templates before any wider rollout.
For specific tasks, our Drafting Agent produces IQ/OQ/PQ and test specs in your templates, and the Requirements Agent turns specifications into testable requirements.
Common mistakes to retire
- Validating the template, not the system. Copying a prior package without revisiting the risk assessment.
- Screenshots as default evidence. They are slow, error-prone and rarely add information the system log does not.
- Traceability done last. A matrix built at the end hides gaps instead of finding them.
- No rationale. Reduced testing without a written reason looks like skipped testing.
- Audit trail never reviewed. Having the feature is not the same as using it.
- Documentation after the fact. Backfilled records fail the contemporaneous test.
If your site runs maintenance systems, our guide on risk-based CMMS validation shows these mistakes in a specific setting.
A note on comma-separated files
Search results for this phrase often cover CSV files, the data format. If you validate data migrations or imports in a GxP context, the format's limits matter. Excel, for example, caps a worksheet at 1,048,576 rows, so a two-million-row file cannot be fully opened in a single sheet. Document the tool you use to process such files, its limits, and how you verified completeness of the import.
FAQ
What does CSV stand for in validation?
In pharma, biotech and medical devices, CSV means computerized (or computerised) system validation: documented evidence that a system does what it is intended to do, consistently. It is a different thing from the comma-separated values file format. Many teams now also use CSA, computer software assurance, for the risk-based way of reaching the same goal.
Is CSA replacing CSV?
CSA is best understood as a change in method, not a new goal. FDA's February 2026 final guidance on CSA covers production and quality system software for medical devices and emphasizes risk-based, least-burdensome assurance. Pharmaceutical teams generally apply GAMP 5 Second Edition, which points the same way. Check which regulation governs your product before choosing your wording.
Do I still need scripted test cases?
Yes, for high-risk functions where a predefined expected result gives you reliable evidence. For lower-risk functions, unscripted or exploratory testing with a recorded objective and outcome can be enough, as long as the risk assessment explains the choice. The rationale is what protects you in an inspection.
Can system logs replace screenshots as test evidence?
Often, yes. FDA's CSA guidance encourages using existing system logs and audit trails as objective evidence, provided the records remain accurate, reliable, complete and authentic. Confirm the log is secure and attributable before relying on it, and keep screenshots only where a visual state is the point of the test.
How often should audit trails be reviewed?
Set the frequency by risk and document it in a procedure. Regulators such as the MHRA expect review to be robust and recorded, either by direct review or by validated exception reporting. Higher-risk data, such as batch release or stability results, warrants more frequent review than low-impact configuration data.
Sources
- FDA: Computer Software Assurance for Production and Quality Management System Software
- FDA CSA guidance text (GMP Compliance)
- CASRAI: GAMP 5 Second Edition changes
- ICH E6(R3) Good Clinical Practice
- EMA guideline on computerised systems and electronic data in clinical trials
- MHRA GxP data integrity guidance
- EudraLex Volume 4, Annex 11: Computerised Systems
- Microsoft: Excel specifications and limits
Recommended
- CSV to CSA: The FDA Transition Playbook for QA Teams
- 7 Inspection Ready CSV Best Practices for Validation Managers
- Inspection Ready CSV Risk Assessment for QA: FDA CSA and ICH Q9(R1)
- 2026 FDA CSA: Audit-Ready Automated Validation Documents for Pharma QA
FAQ
What does CSV stand for in validation?
In pharma, biotech and medical devices, CSV means computerized (or computerised) system validation: documented evidence that a system does what it is intended to do, consistently. It is a different thing from the comma-separated values file format. Many teams now also use CSA, computer software assurance, for the risk-based way of reaching the same goal.
Is CSA replacing CSV?
CSA is best understood as a change in method, not a new goal. FDA's February 2026 final guidance on CSA covers production and quality system software for medical devices and emphasizes risk-based, least-burdensome assurance. Pharmaceutical teams generally apply GAMP 5 Second Edition, which points the same way. Check which regulation governs your product before choosing your wording.
Do I still need scripted test cases?
Yes, for high-risk functions where a predefined expected result gives you reliable evidence. For lower-risk functions, unscripted or exploratory testing with a recorded objective and outcome can be enough, as long as the risk assessment explains the choice. The rationale is what protects you in an inspection.
Can system logs replace screenshots as test evidence?
Often, yes. FDA's CSA guidance encourages using existing system logs and audit trails as objective evidence, provided the records remain accurate, reliable, complete and authentic. Confirm the log is secure and attributable before relying on it, and keep screenshots only where a visual state is the point of the test.
How often should audit trails be reviewed?
Set the frequency by risk and document it in a procedure. Regulators such as the MHRA expect review to be robust and recorded, either by direct review or by validated exception reporting. Higher-risk data, such as batch release or stability results, warrants more frequent review than low-impact configuration data.